AccScience Publishing / IJB / Online First / DOI: 10.36922/IJB026340365
Cite this article
19
Download
402
Views
Related Info Links
More by Authors Links
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
REVIEW ARTICLE

Advanced bioprinting biomaterials for personalized cancer therapy and drug screening: From functional bioinks to precision oncology platforms

Siqi Li1† ,  Renjun Gu1† ,  Xiyi Feng1† ,  Pengfei Li2* ,  Hua Bai3*
Show Less
1 School of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu , China
2 Department of Clinical Laboratory, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu , China
3 School of Acupuncture and Tuina, School of Health Preservation and Rehabilitation, Nanjing University of Chinese Medicine, Nanjing, Jiangsu , China
†These authors contributed equally to this work.
Received: 21 August 2026 | Revised: 16 September 2026 | Accepted: 21 September 2026 | Published online: 22 September 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Three-dimensional (3D) bioprinting is increasingly used to construct patient-relevant tumor models, but its value for precision oncology depends on how functional biomaterials connect tissue reconstruction with therapeutic exposure and response measurement. This review presents a function-oriented framework for advanced bioprinting biomaterials in personalized cancer therapy and drug screening. We define functional biomaterials as printable or print-compatible systems that actively regulate cellular behavior, extracellular-matrix cues, transport, release, microenvironmental adaptation, or response reporting, while distinguishing them from patient-derived biological inputs and enabling technologies. We examine how bioink composition, crosslinking, mechanics, degradation, and spatial patterning influence tumor heterogeneity, stromal interactions, vascular, immune, and hypoxic niches, and therapeutic transport. Particular attention is given to localized drug delivery, nanocomposite and stimuli-responsive systems, sequential exposure, and quantitative evaluation of drug distribution and response. Two representative platforms illustrate how material design can couple microenvironment reconstruction with chemoradiotherapy, chemotherapy, and chimeric antigen receptor-T cell response testing. We also assess patient-derived tumor models for personalized drug testing, including model establishment, heterogeneity preservation, assay reproducibility, and the relationship between ex vivo response and clinical decision-making. Bioink-selection principles and study-level reporting benchmarks are summarized without pooling non-equivalent metrics. Finally, we discuss sample attrition, turnaround time, cost, manufacturing variability, quality control, interlaboratory reproducibility, clinical validation, and regulatory requirements. Clinically useful platforms will be those in which each functional component addresses a defined biological or therapeutic question and generates reproducible, interpretable information, rather than those with the greatest material or architectural complexity.

Keywords
Three-dimensional bioprinting
Functional biomaterials
Bioinks
Patient-derived tumor models
Tumor microenvironment
Drug screening
Personalized cancer therapy
Precision oncology
Funding
This work was supported by the Natural Science Foundation of Jiangsu Province (Grant No. BK20240738), the Basic Science (Natural Science) Research General Program of Jiangsu Provincial Colleges and Universities (Grant No. 24KJB360004), and the Natural Science Foundation Project of Nanjing University of Chinese Medicine (No. XZR2024010).
Conflict of interest
The authors declare no conflicts of interest.
References
  1. Abuwatfa WH, Pitt WG, Husseini GA. Scaffold-based 3D cell culture models in cancer research. J Biomed Sci. 2024;31(1):7. doi: 10.1186/s12929-024-00994-y
  2. Jung M, Ghamrawi S, Du EY, Gooding JJ, Kavallaris M. Advances in 3D bioprinting for cancer biology and precision medicine: from matrix design to application. Adv Healthc Mater. 2022;11(24):2200690. doi: 10.1002/adhm.202200690
  3. Huang Z, Duan X, Ji J, et al. Deconstructing cancer in 3D: models, mechanisms, and personalized solutions. Mol Cancer. 2026;25(1):195. doi: 10.1186/s12943-026-02704-8
  4. Shukla P, Yeleswarapu S, Heinrich MA, Prakash J, Pati F. Mimicking tumor microenvironment by 3D bioprinting: 3D cancer modeling. Biofabrication. 2022;14(3):032002. doi: 10.1088/1758-5090/ac6d11
  5. Branco F, Cunha J, Mendes M, Sousa JOJ, Vitorino C. 3D bioprinting models for glioblastoma: from scaffold design to therapeutic application. Adv Mater. 2025;37(18):2501994. doi: 10.1002/adma.202501994
  6. Lv J, Du X, Wang M, Su J, Wei Y, Xu C. Construction of tumor organoids and their application to cancer research and therapy. Theranostics. 2024;14(3):1101-1125. doi: 10.7150/thno.91362
  7. Dong Y, Zhou X, Ding Y, Luo Y, Zhao H. Advances in tumor microenvironment: applications and challenges of 3D bioprinting. Biochem Biophys Res Commun. 2024;730:150339. doi: 10.1016/j.bbrc.2024.150339
  8. Yang Y, Kong Y, Cui J, Hou Y, Gu Z, Ma C. Advances and applications of cancer organoids in drug screening and personalized medicine. Stem Cell Rev Rep. 2024;20(5):1213-1226. doi: 10.1007/s12015-024-10714-6
  9. Arani RM, Yousefi N, Hamidieh AA, Gholizadeh F, Sisakht MM. Tumor organoid as a drug screening platform for cancer research. Curr Stem Cell Res Ther. 2024;19(9):1210-1250. doi: 10.2174/011574888X268366230922080423
  10. Yang J, Wang L, Wu R, et al. 3D Bioprinting in Cancer Modeling and Biomedicine: From Print Categories to Biological Applications. ACS Omega. 2024;9(44):44076-44100. doi: 10.1021/acsomega.4c06051
  11. Qu J, Kalyani FS, Liu L, Cheng T, Chen L. Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy. Cancer Commun (Lond). 2021;41(12):1331-1353. doi: 10.1002/cac2.12224
  12. Wang Y, Zhang L, Wang LZ, et al. The application of organoids in treatment decision-making for digestive system cancers: progress and challenges. Mol Cancer. 2025;24(1):222. doi: 10.1186/s12943-025-02429-0
  13. Banerjee D, Singh YP, Datta P, et al. Strategies for 3D bioprinting of spheroids: A comprehensive review. Biomaterials. 2022;291:121881. doi: 10.1016/j.biomaterials.2022.121881
  14. Li Y, Liu J, Xu S, Wang J. 3D Bioprinting: An Important Tool for Tumor Microenvironment Research. Int J Nanomedicine. 2023;18:8039-8057. doi: 10.2147/IJN.S435845
  15. Wang X, Luo Y, Ma Y, Wang P, Yao R. Converging bioprinting and organoids to better recapitulate the tumor microenvironment. Trends Biotechnol. 2024;42(5):648-663. doi: 10.1016/j.tibtech.2023.11.006
  16. Xie R, Yang J, Lu X, et al. Physiologically relevant 3D tumor models for therapeutic screening. Biomaterials. 2026;334:124231. doi: 10.1016/j.biomaterials.2026.124231
  17. Mazzaglia C, Shery Huang YY, Shields JD. Advancing tumor microenvironment and lymphoid tissue research through 3D bioprinting and biofabrication. Adv Drug Deliv Rev. 2025;217:115485. doi: 10.1016/j.addr.2024.115485
  18. de Barros NR, Gomez A, Ermis M, et al. Gelatin methacryloyl and laponite bioink for 3D bioprinted organotypic tumor modeling. Biofabrication. 2023;15(4):045005. doi: 10.1088/1758-5090/ace0db
  19. Chakraborty A, Roy A, Ravi SP, Paul A. Exploiting the role of nanoparticles for use in hydrogel-based bioprinting applications: concept, design, and recent advances. Biomater Sci. 2021;9(19):6337-6354. doi: 10.1039/D1BM00605C
  20. Fernandes PD, Silva FC, Magalhães FOD, Pereira RBF, Santos SG, Pinto AM. 3D printing of nanoparticle-containing scaffolds for cancer phototherapy, magnetic hyperthermia therapy, and tissue regeneration. Acta Biomater. 2026;210:221-279. doi: 10.1016/j.actbio.2025.11.043
  21. Iyer KS, Bao L, Zhai J, et al. Microgel-based bioink for extrusion-based 3D bioprinting and its applications in tissue engineering. Bioact Mater. 2025;48:273-293. doi: 10.1016/j.bioactmat.2025.02.003
  22. Hull SM, Lou J, Lindsay CD, et al. 3D bioprinting of dynamic hydrogel bioinks enabled by small molecule modulators. Sci Adv. 2023;9(13):eade7880. doi: 10.1126/sciadv.ade7880
  23. Zhang C, Shen Y, Huang M, et al. Dynamic hydrogel mechanics in organoid engineering: from matrix design to translational paradigms. Bioact Mater. 2026;55:144-170. doi: 10.1016/j.bioactmat.2025.09.021
  24. Wang Y, Duan Y, Yang B, Li Y. Nanocomposite hydrogel bioinks for 3D bioprinting of tumor models. Biomacromolecules. 2024;25(8):5288-5299. doi: 10.1021/acs.biomac.4c00671
  25. Jeong W, Kim D, Wajih N, et al. The effect of stiffness on cell behavior and drug resistance in patient-derived breast cancer organoids. Acta Biomater. 2026;210:27-39. doi: 10.1016/j.actbio.2025.12.026
  26. Blanco-Fernandez B, Bagci G, Perez-Amodio S, et al. A bioprinted breast cancer model using bioinks of decellularized breast tissue for studying cancer stemness, invasion, and drug efficacy. Acta Biomater. 2025;203:306-321. doi: 10.1016/j.actbio.2025.07.054
  27. Yang R, Yu Y. Patient-derived organoids in translational oncology and drug screening. Cancer Lett. 2023;562:216180. doi: 10.1016/j.canlet.2023.216180
  28. Fang T, Cao X, Ibnat M, Chen G. Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing. J Nanobiotechnology. 2022;20(1):354. doi: 10.1186/s12951-022-01570-y
  29. Wei D, Sun Y, Zhu H, Fu Q. Stimuli-Responsive Polymer-Based Nanosystems for Cancer Theranostics. ACS Nano. 2023;17(23):23223-23261. doi: 10.1021/acsnano.3c06019
  30. Vaskovich-Koubi D, Green Buzhor M, Krinsky A, et al. Patient-derived 3D-bioprinted models of pancreatic cancer: toward personalized therapy and overcoming tumor microenvironment challenges. Adv Drug Deliv Rev. 2025;225:115670. doi: 10.1016/j.addr.2025.115670
  31. Jung M, Poltavets V, Skhinas JN, et al. High-throughput 3D engineered paediatric tumour models for precision medicine. Mol Syst Biol. 2025;21(12):1748-1777. doi: 10.1038/s44320-025-00152-y
  32. Li M, Freeman S, Franco-Barraza J, et al. A bioprinted sea-and-island multicellular model for dissecting human pancreatic tumor-stroma reciprocity and adaptive metabolism. Biomaterials. 2024;310:122631. doi: 10.1016/j.biomaterials.2024.122631
  33. Han J, Jeong HJ, Choi J, et al. Bioprinted patient-derived organoid arrays capture intrinsic and extrinsic tumor features for advanced personalized medicine. Adv Sci (Weinh). 2025;12(20):2407871. doi: 10.1002/advs.202407871
  34. Chen H, Wu Z, Gong Z, et al. Acoustic bioprinting of patient-derived organoids for predicting cancer therapy responses. Adv Healthc Mater. 2022;11(13):e2102784. doi: 10.1002/adhm.202102784
  35. Du L, Zheng Z, Zhang K, et al. Exploring personalized prediction of clinical chemotherapy efficacy and revealing tumor heterogeneity using patient-derived 3D bioprinting gastric cancer models. Mol Cancer. 2025;24(1):259. doi: 10.1186/s12943-025-02466-9
  36. Yi HG, Jeong YH, Kim Y, et al. A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses to chemoradiotherapy. Nat Biomed Eng. 2019;3(7):509-519. doi: 10.1038/s41551-019-0363-x
  37. Dey M, Kim MH, Dogan M, et al. Chemotherapeutics and CAR-T Cell-Based Immunotherapeutics Screening on a 3D Bioprinted Vascularized Breast Tumor Model. Adv Funct Mater. 2022;32(52):2203966. doi: 10.1002/adfm.202203966
  38. Germain N, Dhayer M, Dekiouk S, Marchetti P. Current advances in 3D bioprinting for cancer modeling and personalized medicine. Int J Mol Sci. 2022;23(7):3432. doi: 10.3390/ijms23073432
  39. Yu J, Zhang Y, Ran R, et al. Research progress in the field of tumor model construction using bioprinting: a review. Int J Nanomedicine. 2024;19:6547-6575. doi: 10.2147/IJN.S460387
  40. Yao L, Xie P, Huang T, et al. 3D Bioprinting for Tumor Microenvironment Reconstruction: Advances, Challenges, and Future Perspectives. Biotechnol J. 2026;21(6):e70267. doi: 10.1002/biot.70267
  41. Parodi I, Di Lisa D, Pastorino L, Scaglione S, Fato MM. 3D bioprinting as a powerful technique for recreating the tumor microenvironment. Gels. 2023;9(6):482. doi: 10.3390/gels9060482
  42. Aoun J, de Oliveira H, Fennell S, Diab-Assaf M, Caldefie-Chezet F, Delort L. 3D bioprinting for reproducing the tumor microenvironment in cancer research models. Curr Res Biotechnol. 2026;11:100385. doi: 10.1016/j.crbiot.2026.100385
  43. Xu J, Yang S, Su Y, et al. A 3D bioprinted tumor model fabricated with gelatin/sodium alginate/decellularized extracellular matrix bioink. Int J Bioprint. 2022;9(1):630. doi: 10.18063/ijb.v9i1.630
  44. Wang H, Yu H, Zhou X, et al. An overview of extracellular matrix-based bioinks for 3D bioprinting. Front Bioeng Biotechnol. 2022;10:905438. doi: 10.3389/fbioe.2022.905438
  45. Chen Q, Zhou R, Xu Q, Li Z, Tao J. dECM bioinks for 3D bioprinted tumor models: Advances, challenges, and drug screening. iScience. 2026;29(8):117085. doi: 10.1016/j.isci.2026.117085
  46. Tiwari AP, Thorat ND, Pricl S, Patil RM, Rohiwal S, Townley H. Bioink: a 3D-bioprinting tool for anticancer drug discovery and cancer management. Drug Discov Today. 2021;26(7):1574-1590. doi: 10.1016/j.drudis.2021.03.010
  47. Xu H, Zhang S, Song K, Yang H, Yin J, Huang Y. Droplet-based 3D bioprinting for drug delivery and screening. Adv Drug Deliv Rev. 2025;217:115486. doi: 10.1016/j.addr.2024.115486
  48. Gillispie G, Prim P, Copus J, et al. Assessment methodologies for extrusion-based bioink printability. Biofabrication. 2020;12(2):022003. doi: 10.1088/1758-5090/ab6f0d
  49. Miri AK, Mirzaee I, Hassan S, et al. Effective bioprinting resolution in tissue model fabrication. Lab Chip. 2019;19(11):2019-2037. doi: 10.1039/C8LC01037D
  50. Murab S, Gupta A, Włodarczyk-Biegun MGK, et al. Alginate based hydrogel inks for 3D bioprinting of engineered orthopedic tissues. Carbohydr Polym. 2022;296:119964. doi: 10.1016/j.carbpol.2022.119964
  51. Ermis M, Falcone N, Roberto de Barros N, et al. Tunable hybrid hydrogels with multicellular spheroids for modeling desmoplastic pancreatic cancer. Bioact Mater. 2023;25:360-373. doi: 10.1016/j.bioactmat.2023.02.005
  52. Dai X, Liu L, Ouyang J, et al. Coaxial 3D bioprinting of self-assembled multicellular heterogeneous tumor fibers. Sci Rep. 2017;7(1):1457. doi: 10.1038/s41598-017-01581-y
  53. Gugulothu SB, Joseph JP, Chatterjee K. A 3D-bioprinted hydrogel platform with tunable matrix stiffness reveals mechanical adaptation and doxorubicin resistance in triple-negative breast cancer. J Mater Chem B. 2026;14(27):8460-8474. doi: 10.1039/d6tb00892e
  54. Kataki AD, Gupta PG, Cheema U, et al. Mapping tumor-stroma-ECM interactions in spatially advanced 3D models of pancreatic cancer. ACS Appl Mater Interfaces. 2025;17(11):16708-16724. doi: 10.1021/acsami.5c02296
  55. González-Callejo P, Vázquez-Aristizabal P, García-Astrain C, et al. 3D bioprinted breast tumor-stroma models for pre-clinical drug testing. Mater Today Bio. 2023;23:100826. doi: 10.1016/j.mtbio.2023.100826
  56. Yu IS, Li YCE, Chen PY, Chen KT, Lee IC. 3D bioprinted silk fibroin- and hyaluronic acid-based biomimetic extracellular matrices with tunable stiffness regulate glioblastoma invasion and macrophage polarization. Int J Biol Macromol. 2026;379:153883. doi: 10.1016/j.ijbiomac.2026.153883
  57. Choi YM, Na D, Yoon G, et al. Prediction of Patient Drug Response via 3D Bioprinted Gastric Cancer Model Utilized Patient-Derived Tissue Laden Tissue-Specific Bioink. Adv Sci (Weinh). 2025;12(10):e2411769. doi: 10.1002/advs.202411769
  58. Shukla P, Bera AK, Yeleswarapu S, Pati F. High Throughput Bioprinting Using Decellularized Adipose Tissue-Based Hydrogels for 3D Breast Cancer Modeling. Macromol Biosci. 2024;24(8):e2400035. doi: 10.1002/mabi.202400035
  59. Devarasetty M, Mazzocchi AR, Skardal A. Applications of bioengineered 3D tissue and tumor organoids in drug development and precision medicine: current and future. BioDrugs. 2018;32(1):53-68. doi: 10.1007/s40259-017-0258-x
  60. Mierke CT. Bioprinting of cells, organoids and organs-on-a-chip together with hydrogels improves structural and mechanical cues. Cells. 2024;13(19):1638. doi: 10.3390/cells13191638
  61. Bidan NG, Dunsmore G, Ugrinic M, et al. Multicellular tumor spheroid model to study the multifaceted role of tumor-associated macrophages in PDAC. Drug Deliv Transl Res. 2024;14(8):2085-2099. doi: 10.1007/s13346-023-01479-5
  62. Ju M, Jin Z, Yu X, et al. Gastric Cancer Models Developed via GelMA 3D Bioprinting Accurately Mimic Cancer Hallmarks, Tumor Microenvironment Features, and Drug Responses. Small. 2025;21(8):e2409321. doi: 10.1002/smll.202409321
  63. Immohr MB, Dos Santos Adrego F, Teichert HL, et al. 3D-bioprinting of aortic valve interstitial cells: impact of hydrogel and printing parameters on cell viability. Biomed Mater. 2023;18(1):015004. doi: 10.1088/1748-605X/ac9f91
  64. Chang TW, Huang MW, Dong GC, Lee IC. Construction of a 3D bioprinted microfluidic platform to study breast cancer bone metastasis and tumor microenvironmental influences. ACS Appl Mater Interfaces. 2025;17(45):61718-61730. doi: 10.1021/acsami.5c15529
  65. Li J, Parra-Cantu C, Wang Z, Zhang YS. Improving bioprinted volumetric tumor microenvironments In vitro. Trends Cancer. 2020;6(9):745-756. doi: 10.1016/j.trecan.2020.06.002
  66. Bilotta MT, Antignani A, Fitzgerald DJ. Managing the TME to improve the efficacy of cancer therapy. Front Immunol. 2022;13:954992. doi: 10.3389/fimmu.2022.954992
  67. Zhou B, Sun M, Yang M, Cui W, Yang H. Construction and application of multicellular tumor microenvironment models based on three-dimensional bioprinting technology. Hepatobiliary Surg Nutr. 2025;14(4):692-696. doi: 10.21037/hbsn-2025-504
  68. Wu Y, Zhang F, Du F, Huang J, Wei S. Combination of tumor organoids with advanced technologies: a powerful platform for tumor evolution and treatment response (review). Mol Med Rep. 2025;31(6):140. doi: 10.3892/mmr.2025.13505
  69. Bocheng X, França R. Innovative 3D bioprinting approaches for advancing brain science and medicine: a literature review. Biomed Phys Eng Express. 2024;10(6):062002. doi: 10.1088/2057-1976/ad795c
  70. Choi J, Lee EJ, Jang WB, Kwon SM. Development of biocompatible 3D-printed artificial blood vessels through multidimensional approaches. J Funct Biomater. 2023;14(10):497. doi: 10.3390/jfb14100497
  71. Albritton JL, Miller JS. 3D bioprinting: improving in vitro models of metastasis with heterogeneous tumor microenvironments. Dis Model Mech. 2017;10(1):3-14. doi: 10.1242/dmm.025049
  72. Bertassoni LE. Bioprinting of complex multicellular organs with advanced functionality—recent progress and challenges ahead. Adv Mater. 2022;34(3):2101321. doi: 10.1002/adma.202101321
  73. Tayler IM, Stowers RS. Engineering hydrogels for personalized disease modeling and regenerative medicine. Acta Biomater. 2021;132:4-22. doi: 10.1016/j.actbio.2021.04.020
  74. Plava J, Cehakova M, Kuniakova M, et al. The third dimension of tumor microenvironment—the importance of tumor stroma in 3D cancer models. Exp Biol Med (Maywood). 2023;248(15):1347-1358. doi: 10.1177/15353702231198050
  75. Pedron S, Wolter GL, Chen JWE, Laken SE, Sarkaria JN, Harley BAC. Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens. Biomaterials. 2019;219:119371. doi: 10.1016/j.biomaterials.2019.119371
  76. Domingues MF, Carreira MC, Santos MS, et al. A 3D Bioprinted Spheroid-Laden dECM-Enriched Osteosarcoma Model for Enhanced Drug Testing and Therapeutic Discovery. Adv Healthc Mater. 2026;15(15):e03633. doi: 10.1002/adhm.202503633
  77. An S, Jo S, Kim G. A mechanobiology-driven cell-derived ECM bioink for engineering 3D glioblastoma tumor microenvironment models. Theranostics. 2026;16(14):8361-8384. doi: 10.7150/thno.137729
  78. Stecher S, Schenk J, Cianciosi A, et al. 3D Bioprinted Breast Cancer-Stroma Model with Tailored Migration-Permissive Bioink Reveals Impact of Adipose-Derived Stromal Cells on Cancer Cell Migration and Invasion Dynamics. Adv Healthc Mater. 2026;15(30):e71353. doi: 10.1002/adhm.71353
  79. Chen Y, Xue Y, Yan C, et al. Bioprinted Fibroblast Mediated Heterogeneous Tumor Microenvironment for Studying Tumor-Stroma Interaction and Drug Screening. Adv Healthc Mater. 2025;14(7):e2404642. doi: 10.1002/adhm.202404642
  80. Xu K, Huang Y, Wu M, Yin J, Wei P. 3D bioprinting of multi-cellular tumor microenvironment for prostate cancer metastasis. Biofabrication. 2023;15(3):035020. doi: 10.1088/1758-5090/acd960
  81. Rasti Boroojeni F, Naeimipour S, Lifwergren P, et al. Proteolytic remodeling of 3D bioprinted tumor microenvironments. Biofabrication. 2024;16(2):025002. doi: 10.1088/1758-5090/ad17d1
  82. Desigaux T, Comperat L, Dusserre N, et al. 3D bioprinted breast cancer model reveals stroma-mediated modulation of extracellular matrix and radiosensitivity. Bioact Mater. 2024;42:316-327. doi: 10.1016/j.bioactmat.2024.08.037
  83. Krajewska U, Chechlińska M, Kurzyk A. Vascularisation in 3D bioprinted models: emerging solutions engineering functional tissues and tumour models. Biofabrication. 2026;18(2):022001. doi: 10.1088/1758-5090/ae2f02
  84. Zhao Y, Peng Y, Hu R, et al. Seamless vessel-microenvironment bioprinting reveals contact-dependent vascular communications. Trends Biotechnol. 2026;44(7):2140-2169. doi: 10.1016/j.tibtech.2026.02.003
  85. Gao Q, Guo Z, Zhang S, et al. Coaxial bioprinting of microsphere bioink to engineer heterogeneous vascularized lung cancer model. Biomater Adv. 2026;183:214741. doi: 10.1016/j.bioadv.2026.214741
  86. Neufeld L, Yeini E, Reisman N, et al. Microengineered perfusable 3D-bioprinted glioblastoma model for in vivo mimicry of tumor microenvironment. Sci Adv. 2021;7(34):eabi9119. doi: 10.1126/sciadv.abi9119
  87. Grunewald L, Lam T, Andersch L, et al. A reproducible bioprinted 3D tumor model serves as a preselection tool for CAR T cell therapy optimization. Front Immunol. 2021;12:689697. doi: 10.3389/fimmu.2021.689697
  88. Tang M, Xie Q, Gimple RC, et al. Three-dimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions. Cell Res. 2020;30(10):833-853. doi: 10.1038/s41422-020-0338-1
  89. Zimmer J, Castriconi R, Scaglione S. Editorial: recent 3D tumor models for testing immune-mediated therapies. Front Immunol. 2021;12:798493. doi: 10.3389/fimmu.2021.798493
  90. Naoi Y, Inukai Y, Izumikawa T, et al. Close Spatial Interactions between Cancer Cells and Cancer-Associated Fibroblasts Suppress Antitumor Immunity. Cancer Immunol Res. 2025;13(9):1471-1484. doi: 10.1158/2326-6066.cir-24-1144
  91. Andersch L, Grunewald L, Stecklum M, et al. Investigating genetic modifications to enhance L1CAM-CAR T cell migration in solid tumors in a 3D bioprinted neuroblastoma model. Front Immunol. 2025;16:1677361. doi: 10.3389/fimmu.2025.1677361
  92. Sun X, Zhang Z, Zhao W, et al. Prediction of CAR-T Therapy In Vitro: Development of Biomimetic Models for CAR-T Killing Effect Assessment. Small. 2025;21(37):e2503384. doi: 10.1002/smll.202503384
  93. Kim D, Jo S, Lee D, et al. NK cells encapsulated in micro/macropore-forming hydrogels via 3D bioprinting for tumor immunotherapy. Biomater Res. 2023;27(1):60. doi: 10.1186/s40824-023-00403-9
  94. Morley CD, Flores CT, Drake JA, Moore GL, Mitchell DA, Angelini TE. Spatiotemporal T cell dynamics in a 3D bioprinted immunotherapy model. Bioprinting. 2022;28:e00231. doi: 10.1016/j.bprint.2022.e00231
  95. Heinrich MA, Bansal R, Lammers T, Zhang YS, Michel Schiffelers R, Prakash J. 3D-bioprinted mini-brain: a glioblastoma model to study cellular interactions and therapeutics. Adv Mater. 2019;31(14):e1806590. doi: 10.1002/adma.201806590
  96. Tung YT, Chen YC, Derr K, Wilson K, Song MJ, Ferrer M. A 3D Bioprinted Human Neurovascular Unit Model of Glioblastoma Tumor Growth. Adv Healthc Mater. 2024;13(15):e2302831. doi: 10.1002/adhm.202302831
  97. Yao EJ, Lu GY, Vadla R, et al. Forming a Precise and Reproducible Hypoxic Tumor Microenvironment in Glioblastoma by High Cell Density Bioprinting. Adv Healthc Mater. 2026;15(26):e71322. doi: 10.1002/adhm.71322
  98. Wang X, Yang X, Liu Z, et al. 3D bioprinting of an in vitro hepatoma microenvironment model: Establishment, evaluation, and anticancer drug testing. Acta Biomater. 2024;185:173-189. doi: 10.1016/j.actbio.2024.07.019
  99. Devarasetty M, Wang E, Soker S, Skardal A. Mesenchymal stem cells support growth and organization of host-liver colorectal-tumor organoids and possibly resistance to chemotherapy. Biofabrication. 2017;9(2):021002. doi: 10.1088/1758-5090/aa7484
  100. Zhang Z, Chen X, Gao S, Fang X, Ren S. 3D bioprinted tumor model: a prompt and convenient platform for overcoming immunotherapy resistance by recapitulating the tumor microenvironment. Cell Oncol (Dordr). 2024;47(4):1113-1126. doi: 10.1007/s13402-024-00935-9
  101. Kim D, Jo S, Jang I, et al. Bioprinted Tumor Microenvironment Models Reveal Immune Evasion and Guide CAR-NK Therapeutic Strategies. Adv Sci (Weinh). 2026;13(36):e202521188. doi: 10.1002/advs.202521188
  102. Wang P, Sun L, Li C, et al. Study on drug screening multicellular model for colorectal cancer constructed by three-dimensional bioprinting technology. Int J Bioprint. 2023;9(3):694. doi: 10.18063/ijb.694
  103. Ozturk MS, Lee VK, Zou H, Friedel RH, Intes X, Dai G. High-resolution tomographic analysis of in vitro 3D glioblastoma tumor model under long-term drug treatment. Sci Adv. 2020;6(10):eaay7513. doi: 10.1126/sciadv.aay7513
  104. Liu C, Shi C, Wang S, et al. Bridging the gap: how patient-derived lung cancer organoids are transforming personalized medicine. Front Cell Dev Biol. 2025;13:1554268. doi: 10.3389/fcell.2025.1554268
  105. Uwimana A, Gnecco G, Riccaboni M. Artificial intelligence for breast cancer detection and its health technology assessment: a scoping review. Comput Biol Med. 2025;184:109391. doi: 10.1016/j.compbiomed.2024.109391
  106. Chen H, Zhang B, Huang J. Recent advances and applications of artificial intelligence in 3D bioprinting. Biophys Rev. 2024;5(3):031301. doi: 10.1063/5.0190208
  107. Wang J, Wang F, Jiang Y, Bai L, Chen X, Su J. Organoid-driven nanomedicine platform development. Biomaterials. 2026;325:123611. doi: 10.1016/j.biomaterials.2025.123611
  108. Shboul SA, DeLuca VJ, Dweiri YA, Saleh T. Can 3D bioprinting solve the mystery of senescence in cancer therapy? Ageing Res Rev. 2022;81:101732. doi: 10.1016/j.arr.2022.101732
  109. Masoumi Shahrbabak S, Jalali SM, Fathabadi MF, et al. Modified alginates for precision drug delivery: Advances in controlled-release and targeting systems. Int J Pharm X. 2025;10:100381. doi: 10.1016/j.ijpx.2025.100381
  110. Fu Y, Bian X, Li P, Huang Y, Li C. Carrier-Free Nanomedicine for Cancer Immunotherapy. J Biomed Nanotechnol. 2022;18(4):939-956. doi: 10.1166/jbn.2022.3315
  111. Liu JY, Zheng YY, Wang SY, et al. Advances in carrier-free nanodrug delivery systems. Drug Deliv Transl Res. 2026;16(8):2603-2621. doi: 10.1007/s13346-026-02118-5
  112. An J, Zhang Z, Zhang J, Zhang L, Liang G. Research progress in tumor therapy of carrier-free nanodrug. Biomed Pharmacother. 2024;178:117258. doi: 10.1016/j.biopha.2024.117258
  113. Zhang X, Hu S, Huang L, et al. Advance Progress in Assembly Mechanisms of Carrier-Free Nanodrugs for Cancer Treatment. Molecules. 2023;28(20):7065. doi: 10.3390/molecules28207065
  114. Guo Q, Lai L, Huang L, et al. Microfluidic fabrication of peptide modified carrier-free self-assembled crizotinib-metal nanodrugs for NIR fluorescence imaging and dual-pathway therapy of non-small cell lung cancer. J Colloid Interface Sci. 2026;711:140086. doi: 10.1016/j.jcis.2026.140086
  115. Fu N, Guo L, Zhou S, et al. Cinnamaldehyde-Based Self-Assembled Nanodrugs with GSH Depletion for Antitumor through Photodynamic Therapy Enhanced Ferroptosis and Immunotherapy. ACS Appl Mater Interfaces. 2026;18(14):20247-20264. doi: 10.1021/acsami.6c01928
  116. Zhao H, Yang C, Bao S, et al. Fe3+ loaded mastoparan M - ICG nanoassemblies for synergistic breast cancer therapy via photothermal and chemodynamic therapy-assisted oxidation stress. iScience. 2026;29(8):116740. doi: 10.1016/j.isci.2026.116740
  117. Cai S, Zhao J, Liu H, et al. Near-infrared light-triggered, self-amplifying targeted drug-delivery platform achieves precision treatment of retinoblastoma. Int J Pharm. 2026;701:127076. doi: 10.1016/j.ijpharm.2026.127076
  118. Troncoso-Afonso L, Vázquez-Aristizabal P, Vinnacombe-Willson GA, et al. dECM-Supported Printing of Plasmonic Pillars for SERS Monitoring of Chemotherapy in 3D Tumor Models. ACS Sens. 2025;10(9):7114-7123. doi: 10.1021/acssensors.5c02344
  119. Shahpouri M, Adili-Aghdam MA, Mahmudi H, et al. Prospects for hypoxia-based drug delivery platforms for the elimination of advanced metastatic tumors: From 3D modeling to clinical concepts. J Control Release. 2023;353:1002-1022. doi: 10.1016/j.jconrel.2022.12.009
  120. Zhang J, Luo X, Sun Z, Jin B, Zhao Y. Tumor Assembloids as Three-Dimensional Platforms for Modeling Drug Delivery Barriers: Construction Strategies, Applications, and Translational Challenges. Drug Des Devel Ther. 2026;20:1-16. doi: 10.2147/dddt.s618870
  121. Ingber DE. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat Rev Genet. 2022;23(8):467-491. doi: 10.1038/s41576-022-00466-9
  122. Marx U. Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. ALTEX. 2020;37(3):365-394. doi: 10.14573/altex.2001241
  123. Herranz-Ors C, Bhosle SG, Beck AE, et al. A tumour-derived organoid biobank maps cancer gene dependencies. Nature. 2026;657(8132):765-774. doi: 10.1038/s41586-026-10830-y
  124. Letai A, Bhola P, Welm AL. Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell. 2022;40(1):26-35. doi: 10.1016/j.ccell.2021.12.004
  125. Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920-926. doi: 10.1126/science.aao2774
  126. Maloney E, Clark C, Sivakumar H, et al. Immersion bioprinting of tumor organoids in multi-well plates for increasing chemotherapy screening throughput. Micromachines (Basel). 2020;11(2):208. doi: 10.3390/mi11020208
  127. Yang R, Wang S, Li Z, Yin C, Huang W, Huang W. Patient-derived organoid co-culture systems as next-generation models for bladder cancer stem cell research. Cancer Lett. 2025;625:217793. doi: 10.1016/j.canlet.2025.217793
  128. Liu B, Cheng H, Yu K, et al. Biomimetic 3D-Bioprinted organoids of thymic epithelial tumors for translational drug screening and biomarker identification. Mater Today Bio. 2026;37:102878. doi: 10.1016/j.mtbio.2026.102878
  129. Zhao Y, Li Y, Zhang W, et al. 3D-bioprinted liver cancer models derived from primary hepatocytes for simulating cancer initiation and drug screening. Hepatol Commun. 2025;9(11):e0823. doi: 10.1097/hc9.0000000000000823
  130. Rizwan M, Mei X, Cai L, et al. A 3D-bioprinted head and neck cancer model for drug screening. Biomed Mater. 2026;21(4):045004. doi: 10.1088/1748-605x/ae8069
  131. Kremneva E, Smolander J, Peltokangas M, et al. Precision tumor-on-chip for personalized assessment of drug efficacy and immune cell delivery. Cell Rep Methods. 2026;6(8):101475. doi: 10.1016/j.crmeth.2026.101475
  132. Tong F, Nie R, Wu Z, et al. Construction of 3D bioprinted colorectal cancer models and evaluation of their efficacy and drug sensitivity. APL Bioeng. 2026;10(3):036101. doi: 10.1063/5.0320497
  133. Tang M, Jiang S, Huang X, et al. Integration of 3D bioprinting and multi-algorithm machine learning identified glioma susceptibilities and microenvironment characteristics. Cell Discov. 2024;10(1):39. doi: 10.1038/s41421-024-00650-7
  134. Diosdi A, Toth T, Harmati M, et al. HCS-3DX, a next-generation AI-driven automated 3D-oid high-content screening system. Nat Commun. 2025;16(1):8897. doi: 10.1038/s41467-025-63955-5
  135. Becceneri AB, Liu S, Yildirim S, et al. Advancing photocytotoxicity evaluation of nitric oxide derivative-ruthenium complex in 3D biofabricated breast cancer models. Mater Today Bio. 2026;39:103348. doi: 10.1016/j.mtbio.2026.103348
  136. Scrocciolani C, Caserio L, Grillo S, et al. 3D Bioprinting of High-Grade Serous Ovarian Cancer Cells: Workflow for Gelatin-Based Bioink Formulation with Hyaluronic Acid and Printability Assessment. ACS Appl Bio Mater. 2026;9(14):6370-6387. doi: 10.1021/acsabm.6c00299
  137. Kirac MK, Bilge B, Ozdil CC, Tugcu T, Ulgen KO. 3D bioprinted melanoma constructs reveal delivery-dependent efficacy of phytochemical-gold nanoparticle formulations. Biomed Mater. 2026;21(3):035004. doi: 10.1088/1748-605x/ae5ee7
  138. Xu K, Wu J, Li Z, Chen W, Wei P, Wu M. The application of 3D cell culture for melanoma in vitro models. Acta Biomater. 2026;209:148-166. doi: 10.1016/j.actbio.2025.11.039
  139. Kim GM, Lee Y, Park S, Kim I, Lee HR, Jung S. 3-Layer lung cancer invasion model for evaluating MMP-targeted anti-metastatic therapeutics. Biomed Mater. 2026. doi: 10.1088/1748-605x/ae834f
  140. Si W, Zhou J, Jiang M. Lung cancer organoids for functional precision oncology: from disease modeling to clinical decision support. Front Oncol. 2026;16:1864153. doi: 10.3389/fonc.2026.1864153
  141. Majumder R, Datta P, Moolayadukkam S, Puri IK. Repurposing Alzheimer's and ovarian cancer drugs as sonosensitizers for glioblastoma via a positive-unlabeled learning and 3D bioprinting-based new approach methodology (NAM). PLoS One. 2026;21(8):e0354981. doi: 10.1371/journal.pone.0354981
  142. du Plessis J, Omar A. Patient-Derived Organoid-Based CRISPR Screens in Cancer Research: Applications, Advances, and Challenges. Cancer Med. 2026;15(8):e72112. doi: 10.1002/cam4.72112
  143. Mao S, Xie R, Shou J, Pang Y, Sun W. Bioprinting of patient-derived heterogeneous renal cell carcinoma organoids for personalized therapy. Biofabrication. 2025;17(4):045012. doi: 10.1088/1758-5090/adecc5
  144. Dai R, Chen W, Chen Y, et al. 3D bioprinting platform development for high-throughput cancer organoid models construction and drug evaluation. Biofabrication. 2024;16(3):035012. doi: 10.1088/1758-5090/ad51a6
  145. Mazzocchi A, Soker S, Skardal A. 3D bioprinting for high-throughput screening: drug screening, disease modeling, and precision medicine applications. Appl Phys Rev. 2019;6(1):011302. doi: 10.1063/1.5056188
  146. Xia Y, Chen H, Li J, et al. Acoustic Droplet-Assisted Superhydrophilic-Superhydrophobic Microarray Platform for High-Throughput Screening of Patient-Derived Tumor Spheroids. ACS Appl Mater Interfaces. 2021;13(20):23489-23501. doi: 10.1021/acsami.1c06655
  147. Ali ASM, Wu D, Bannach-Brown A, et al. 3D bioprinting of liver models: a systematic scoping review of methods, bioinks, and reporting quality. Mater Today Bio. 2024;26:100991. doi: 10.1016/j.mtbio.2024.100991
  148. Grijalva Garces D, Strauß S, Gretzinger S, et al. On the reproducibility of extrusion-based bioprinting: round robin study on standardization in the field. Biofabrication. 2024;16(1):015002. doi: 10.1088/1758-5090/acfe3b
  149. Agarwal T, Onesto V, Banerjee D, et al. 3D bioprinting in tissue engineering: current state-of-the-art and challenges towards system standardization and clinical translation. Biofabrication. 2025;17(4):042003. doi: 10.1088/1758-5090/ade47a
  150. Yang K, Wang L, Vijayavenkataraman S, Yuan Y, Tan ECK, Kang L. Recent applications of three-dimensional bioprinting in drug discovery and development. Adv Drug Deliv Rev. 2024;214:115456. doi: 10.1016/j.addr.2024.115456
  151. Zhang Y, Huang Z, Wang B, Li B, Yang Y. Three-dimensional bioprinted organoids: advances and clinical translation. Regen Biomater. 2026;13:rbag142. doi: 10.1093/rb/rbag142
  152. Li Y, Shi J, Zhang Q, Huang H, Zhou S. Three-Dimensional Bioprinting-Enabled Organoids for Engineering the Tumor Microenvironment. Tissue Eng Part B Rev. 2026. doi: 10.1177/19373368261469463
  153. Michael B, Jayaprakash N, Munivel N, Jaisankar D. 3D printing in drug delivery: emerging technologies, clinical translation, and the future of personalized medicine. Med Drug Discov. 2026;29:100242. doi: 10.1016/j.medidd.2025.100242
  154. Piotrowska U, Tsoi J, Singh P, Banerjee A, Sobczak M. 3D bioprinting and artificial intelligence for tumor microenvironment modeling: a scoping review of models, methods, and integration pathways. Mol Pharm. 2025;22(10):5801-5823. doi: 10.1021/acs.molpharmaceut.5c01062
  155. Zhang Z, Zhou X, Fang Y, Xiong Z, Zhang T. AI-driven 3D bioprinting for regenerative medicine: from bench to bedside. Bioact Mater. 2025;45:201-230. doi: 10.1016/j.bioactmat.2024.11.021
  156. Jaiswal C, Dey S, Prasad J, Gupta R, Agarwala M, Mandal BB. 3D bioprinted microfluidic based osteosarcoma-on-a chip model as a physiomimetic pre-clinical drug testing platform for anti-cancer drugs. Biomaterials. 2025;320:123267. doi: 10.1016/j.biomaterials.2025.123267
  157. Zhang C, Yang J, Xiao X, Yu W, Cai X. Spatial architecture and dynamic surveillance: 3D bioprinting and microfluidics converge to overcome digestive malignancies. Hepatobiliary Surg Nutr. 2026;15(4):115. doi: 10.21037/hbsn-2026-0598
  158. Strepi K, Koppenol RF, Jonkers J, Houthuijzen JM. Beyond the traditional dish: Advanced 3D ex vivo culture platforms for tumor modelling. Semin Cancer Biol. 2026;125:62-74. doi: 10.1016/j.semcancer.2026.07.002
  159. Murucci MD, Onikanni SA, da Cunha Goldstein A, et al. 3D bioprinted connections in Liver-Pancreas crosstalk: Lessons learned and future directions. Mol Cell Endocrinol. 2026;618:112806. doi: 10.1016/j.mce.2026.112806
  160. Ibrahim MS, Kim M. Artificial Intelligence-Aided Microfluidic Cell Culture Systems. Biosensors (Basel). 2025;16(1):16. doi: 10.3390/bios16010016
  161. Xie T, Huang A, Yan H, Ju X, Xiang L, Yuan J. Artificial intelligence: illuminating the depths of the tumor microenvironment. J Transl Med. 2024;22(1):799. doi: 10.1186/s12967-024-05609-6
  162. Lee JS, Cha JH, Kim BS. Artificial intelligence in 3D bioprinting and biofabrication: a validation-stringency assessment. Biofabrication. 2026;18(3):032003. doi: 10.1088/1758-5090/ae7b07
  163. Ashique S, Garg A, Islam A, et al. Exploring the role of 4D printing materials, techniques, and characteristics for personalized oncology. Transl Oncol. 2026;70:102818. doi: 10.1016/j.tranon.2026.102818
Share
Back to top
International Journal of Bioprinting, Electronic ISSN: 2424-8002 Print ISSN: 2424-7723, Published by AccScience Publishing